NURO - NeuroMetrix Inc Stock Price, Fair Value and News

$3.900.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NURO Price Action

Last 7 days

2.4%

Last 30 days

-10.1%

Last 90 days

-0.8%

Trailing 12 Months

16.4%

NURO RSI Chart

NURO Valuation

Market Cap

8.0M

Price/Earnings (Trailing)

-1.04

Price/Sales (Trailing)

2.11

EV/EBITDA

-0.64

Price/Free Cashflow

-1.06

NURO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NURO Fundamentals

NURO Revenue

Revenue (TTM)

3.8M

Rev. Growth (Yr)

-51.19%

Rev. Growth (Qtr)

-23.64%

NURO Earnings

Earnings (TTM)

-7.7M

Earnings Growth (Yr)

14.73%

Earnings Growth (Qtr)

-1.36%

NURO Profitability

Operating Margin

57.56%

EBT Margin

-265.61%

Return on Equity

-48.03%

Return on Assets

-44.65%

Free Cashflow Yield

-94.77%

NURO Investor Care

Shares Dilution (1Y)

90.21%

Diluted EPS (TTM)

-4.57

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.3M	4.4M	3.8M	0
2023	7.7M	7.2M	6.4M	5.9M
2022	8.4M	8.3M	8.2M	8.3M
2021	7.4M	8.2M	8.2M	8.3M
2020	6.5M	6.5M	6.5M	7.4M
2019	17.0M	14.6M	13.0M	10.1M
2018	17.5M	17.0M	17.1M	16.0M
2017	14.1M	15.7M	15.9M	17.1M
2016	8.3M	9.7M	11.0M	12.0M
2015	5.5M	5.3M	6.0M	7.3M
2014	5.2M	5.4M	5.5M	5.5M
2013	6.9M	5.8M	5.4M	5.3M
2012	9.6M	9.2M	8.4M	7.6M
2011	13.2M	12.0M	11.1M	10.4M
2010	0	22.1M	18.0M	13.9M
2009	0	0	0	26.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About NeuroMetrix Inc

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

CEO	Dr. Shai N. Gozani M.D., Ph.D.
WEBSITE	neurometrix.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	27

NeuroMetrix Inc Frequently Asked Questions

What is the ticker symbol for NeuroMetrix Inc? What does NURO stand for in stocks?

NURO is the stock ticker symbol of NeuroMetrix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroMetrix Inc (NURO)?

As of Fri Dec 20 2024, market cap of NeuroMetrix Inc is 7.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NURO stock?

You can check NURO's fair value in chart for subscribers.

Is NeuroMetrix Inc a good stock to buy?

The fair value guage provides a quick view whether NURO is over valued or under valued. Whether NeuroMetrix Inc is cheap or expensive depends on the assumptions which impact NeuroMetrix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NURO.

What is NeuroMetrix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, NURO's PE ratio (Price to Earnings) is -1.04 and Price to Sales (PS) ratio is 2.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NURO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeuroMetrix Inc's stock?

In the past 10 years, NeuroMetrix Inc has provided -0.507 (multiply by 100 for percentage) rate of return.